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An optimised direct lysis method 
for gene expression studies on low 
cell numbers
Anh Viet-Phuong Le1,2, Dexing Huang1, Tony Blick1, Erik W. Thompson1,3,4 & 
Alexander Dobrovic2,5,6
There is increasing interest in gene expression analysis of either single cells or limited numbers of 
cells. One such application is the analysis of harvested circulating tumour cells (CTCs), which are 
often present in very low numbers. A highly efficient protocol for RNA extraction, which involves a 
minimal number of steps to avoid RNA loss, is essential for low input cell numbers. We compared 
several lysis solutions that enable reverse transcription (RT) to be performed directly on the cell 
lysate, offering a simple rapid approach to minimise RNA loss for RT. The lysis solutions were 
assessed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in low cell 
numbers isolated from four breast cancer cell lines. We found that a lysis solution containing both 
the non-ionic detergent (IGEPAL CA-630, chemically equivalent to Nonidet P-40 or NP-40) and bovine 
serum albumin (BSA) gave the best RT-qPCR yield. This direct lysis to reverse transcription protocol 
outperformed a column-based extraction method using a commercial kit. This study demonstrates a 
simple, reliable, time- and cost-effective method that can be widely used in any situation where RNA 
needs to be prepared from low to very low cell numbers.
Circulating tumour cells (CTCs) are thought to play a critical role in cancer dissemination1,2. The detec-
tion and enumeration of CTCs offers prognostic value in many cancers including breast cancer3, prostate 
cancer4 and colorectal cancer5. Molecular characterisation of CTCs is an emerging field in cancer and 
holds great promise in assisting the current understanding of cancer metastasis6.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) has been regularly employed 
for the detection and characterisation of CTCs7–10. This technique allows the amplification from samples 
containing small amount of transcripts and can be multiplexed for the analysis of multiple gene targets 
simultaneously10. Since CTCs are rare in the bloodstream, optimising RNA yield from isolated CTCs 
prior to RT-qPCR is essential. As mRNA loss is likely to occur during column-based extraction, direct 
lysis methods in which reverse transcription can be performed directly on the cell lysate are an attractive 
alternative. Direct lysis methods also offer a simpler, cheaper and faster approach of preparing RNA to 
study gene expression profiles of CTCs, especially for single cells or small numbers of cells.
Eaton et al. was the first study reporting a direct lysis method for the analysis of isolated CTCs by 
RT-PCR11. It showed the compatibility of the plasma-membrane solubilising detergent Nonidet P-40 
(octylphenoxy poly(ethyleneoxy)ethanol, sometimes called NP-40) with downstream RT-PCR. Since 
then, Nonidet P-40 has been utilised in other CTC studies across several cancer types, including colorec-
tal cancer12, head and neck squamous cell carcinoma13 and breast cancer14,15. The original reagent has 
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become unavailable and has been replaced with the chemically equivalent compound IGEPAL CA-630. 
A recent study by Svec et al. compared 17 different lysis solutions (including a IGEPAL CA-630 based 
lysis buffer) for a small number of astrocytes and found that a lysis solution containing bovine serum 
albumin (BSA) in water gave the best RT-qPCR performance16.
We had previously used a Nonidet P-40 based lysis solution that contained components of the subse-
quent reverse transcriptase reaction (RT mix A), including an RNase inhibitor and dithiothreitol (DTT) 
as RNA protective agents11,12,14,15. In the current study, we sought to test whether the BSA based lysis 
solution of Svec et al. was superior to IGEPAL CA-630 based lysis solutions for gene expression analysis 
by RT-qPCR from small numbers of breast cancer cells such as might be isolated after enrichment for 
CTCs, and whether a combination of the two (i.e., IGEPAL CA-630/BSA) might further improve the 
results. We compared lysis solutions (0.3% IGEPAL CA-630 alone, 0.3% IGEPAL CA-630 in RT mix A, 
0.1% BSA alone, the combination of 0.3% IGEPAL CA-630 and 0.1% BSA, and water) for their capacity 
to release and protect mRNA from low cell numbers of different breast cancer cell lines and for their 
compatibility for downstream RT-qPCR. We demonstrated that IGEPAL CA-630/BSA lysis solution per-
formed the best and was also superior to a commercially available column-based methodology for small 
numbers of cells.
Results
Comparison of lysis solutions for small numbers of MDA-MB-468 human breast cancer 
cells. We tested the ability of five different lysis solutions to lyse a small number of MDA-MB-468 
breast cancer cells, and their compatibility with downstream RT-qPCR. The lysis solutions were 0.3% 
IGEPAL CA-630 in RT mix A, 0.3% IGEPAL CA-630 alone, 0.1% BSA alone, 0.3% IGEPAL CA-630 and 
0.1% BSA combined, and water. “IGEPAL CA-630 in RT mix A” is a modification of our original lysis 
solution as per Eaton et al.11. It consists of SUPERase• In™ RNase inhibitor, DTT and pooled gene spe-
cific primers, rather than hexamers used in the original protocol. This was made with the rationale that 
Nonidet P-40 was established as an effective cell membrane lysis reagent and that SUPERase• In™ and 
DTT would help to protect the RNA from degradation after the cell membrane was lysed. Alternatively, 
IGEPAL CA-630 in water alone was added directly to cell pellets as used by Svec et al.16. Similarly, lysis 
solutions with BSA alone, IGEPAL CA-630/BSA, and water were used directly to lyse cell pellets and the 
RT mix was added 5 minutes after lysis on ice.
Each of the lysis solutions was applied to three cell pellets containing approximately one hundred 
cells, which had been collected by serial dilution and subsequent centrifugation (350 × g for 5 min). To 
minimise potential differences in cell inputs for each lysis solution, five samples of one hundred cells had 
been pelleted, from each of three replicate serial dilutions.
Transcript levels of ribosomal protein L32 (RPL32) and epidermal growth factor receptor (EGFR), 
which are highly expressed in the MDA-MB-468 cell line, were measured by RT-qPCR. Highly expressed 
genes were chosen to avoid issues with stochastic gene expression, which can be a problem when work-
ing with very small numbers of cells. Sample preparation and the subsequent RT-qPCR were performed 
simultaneously to avoid batch-to-batch variation. The results shown in Fig. 1 are the average of the three 
replicates.
Consistent with the findings of Svec et al.16, the lysis solution with BSA alone gave earlier amplifica-
tion than that with IGEPAL CA-630 alone (Fig. 1). The lysis solution that included components of the 
RT mix in addition to IGEPAL CA-630 performed slightly better than IGEPAL CA-630 alone (Fig. 1), but 
the difference was marginal. IGEPAL CA-630/BSA in the lysis mix gave the best RT-qPCR performance 
for both genes, although the improvement over BSA alone was marginal. This was more than 3 Cts better 
than water alone, an approximately 10-fold difference.
Comparison of lysis solutions for small numbers of various human breast cancer cell lines. We 
expanded the comparison of the effectiveness of the lysis solutions to a further three breast cancer cell 
lines from several intrinsic subtypes17,18. BT549 and MDA-MB-231 are basal B breast cancer cell lines, 
MDA-MB-468 is a basal A breast cancer cell line and MCF7 is a luminal breast cancer cell line.
For each cell line, replicates of approximately one hundred cells were prepared by serial dilution, on 
which each of the five lysis solutions were tested in duplicate. RT-qPCR was performed for RPL32 and 
EGFR for all cell lines. EGFR expression was not detected in MCF7 in our study, as expected, given its 
low to absent gene expression in luminal breast cancer cell lines19. Since MCF7 is an estrogen receptor 
positive cell line, we compared the five lysis solutions using RT-qPCR for estrogen receptor 1 (ESR1). 
The results, from two experimental replicates, across all transcripts and cell lines were consistent, in that 
water gave the highest raw Ct values (the worst RNA yield) for RT-qPCR, followed by lysis solutions 
containing IGEPAL CA-630 (alone and in RT mix). Once again, although the lysis solution containing 
BSA alone performed well, the IGEPAL CA-630/BSA lysis solution gave the lowest Ct values (Fig. 2). For 
both the RPL32 and EGFR data, the difference in RNA yield between IGEPAL CA-630/BSA and each 
of IGEPAL CA-630 alone, IGEPAL CA-630 in RT mix, and water alone, as measured by RT-qPCR, was 
statistically significant in the post-hoc test following the repeated measures one-way ANOVA. In the 
same post-hoc test, the difference between IGEPAL CA-630/BSA and BSA alone was only significant in 
the EFGR data (p < 0.05).
www.nature.com/scientificreports/
3Scientific RepoRts | 5:12859 | DOi: 10.1038/srep12859
Comparison of direct lysis with column-based RNA extraction for small numbers of 
cells. RNA extraction using the Arcturus PicoPure kit has been widely used to extract RNA from 
limited material obtained by laser capture microdissection20–22 and more recently from CTCs23,24. Since 
RNA extraction using a direct lysis method could minimise RNA loss and is more cost and time effective, 
we compared IGEPAL CA-620/BSA lysis solution, which gave the best results in the previous sections, 
against the Arcturus PicoPure kit. Initially, we applied these two methods on cell pellets containing 
approximately one hundred MDA-MB-468 cells. Raw Ct values obtained by RT-qPCR for RPL32 and 
EGFR mRNA were used to compare the two methods. The experiment was performed twice, each with 
two replicates. We observed similar results for all repeats and replicates. Samples lysed directly with 
IGEPAL CA-630/BSA gave earlier Ct values, between one and two cycles, than those from the column 
extraction method, for both RPL32 and EGFR (Fig. 3).
We then compared the two methods across a range of cell numbers (10, 100, and 1,000 MDA-MB-468 
cells), with two replicates at each cell number, for each method. Raw Ct values obtained by RT-qPCR for 
RPL32 mRNA were used for the comparison. The relative effectiveness of the Arcturus PicoPure kit was 
consistent across the range of cell numbers tested, as reflected by the Ct values. At 10 and 100 cells in 
the dilution series, Ct values from directly lysed samples came up 1.8 cycles earlier than those from the 
Arcturus PicoPure column extraction method. At 1,000 cells, the difference in the mean Ct value was 1 
Ct in favour of the lysis method (Fig. 4), indicating a possible decrease in efficiency of the lysis method 
at higher cell numbers. The difference in RNA yield, as measured by RT-qPCR, across the various cell 
numbers tested was statistically significant (p < 0.05).
Discussion
Several methods that facilitate the isolation of RNA from very low numbers of cells for gene expression 
analysis have been published. Low numbers of cells require a procedure that minimises RNA loss during 
the RNA extraction step and thus gives the best RNA yield for RT-qPCR. Generally, direct lysis methods 
that avoid the use of columns and precipitation steps have been used to minimise the loss of RNA.
We compared direct lysis methods using low numbers of cells from several breast cancer cell lines by 
RT-qPCR. Our results showed that water alone gave the worst results, as would be expected. The lysis 
solutions containing IGEPAL CA-630 in water or in RT mix both performed markedly better, but could 
not be readily differentiated from each other. The lysis solution with BSA alone generally performed 
better than that with IGEPAL CA-630, consistent with the results by Svec et al. for astrocytes16, indicating 
that this is likely to be the case for multiple cell types. We further found that the combination of IGEPAL 
CA-630 and BSA gave improved RNA yields over either alone, as measured by RT-qPCR, across all the 
cell lines tested, from several intrinsic breast cancer subtypes.
Figure 1. Comparison of five different lysis solutions for small number of MDA-MB-468 breast cancer 
cells. Three replicate samples of approximately one hundred cells were subjected to each different lysis 
solution, RT-qPCR was run and threshold cycle (Ct) values were determined for RPL32 and EGFR. The 
earliest Ct values of IGEPAL CA-630/BSA indicate that it performed the best. Conversely, the latest Ct 
values for samples lysed in water indicate that it performed the worse. Lysis with BSA alone led to earlier Ct 
values than those obtained from lysis with IGEPAL CA-630 alone or IGEPAL CA-630 in RT mix. Error bars 
represent standard deviation (SD). Mean and SD values are shown on top of the corresponding bars.
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Figure 2. Comparison of different lysis solutions on small cell numbers of various breast cancer cell 
lines. For each cell line, replicates of approximately one hundred cells were subjected to each of the lysis 
solution. RT-qPCR was run and threshold cycle (Ct) values were determined for (a) RPL32 and (b) EGFR or 
ESR1. In all cases, the lysis solution with IGEPAL CA-630/BSA gave the earliest Ct values, followed by that 
with BSA alone. Lysing with water alone gave the worst Ct values. Error bars are the standard error of the 
means (SEM) from two experimental replicates.
www.nature.com/scientificreports/
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Interestingly, our previous methodology using IGEPAL CA-630 and RNA-protective components of 
the RT mix did not perform better than the lysis solution using IGEPAL CA-630 alone (Fig. 1). It is how-
ever possible that the advantage of the protective reagents might be magnified under less optimal condi-
tions than those used here, such as in long term storage of cell pellets, or samples with high RNase levels.
Since one of the most common approaches to extract RNA is column-based, we compared the 
IGEPAL CA-630/BSA lysis solution with the commercial extraction kit commonly used for small number 
of cells, the Arcturus PicoPure kit, and found an enhancement of at least 1 Ct. Since Ct values represent 
a negative log scale, at least one Ct earlier equates to at least double the RNA yield. Moreover, while the 
Figure 3. Comparison between direct lysis and a column-based RNA extraction for one hundred 
breast cancer cells. Direct lysis and column RNA extraction were each performed on two replicates of 
approximately one hundred MDA-MB-468 cells, followed by RT-qPCR RPL32 and EGFR. The direct lysis 
method gave at least 1 Ct earlier than the column-based method. The experiment was performed twice. 
Error bars represent standard error of the means (SEM). Mean and SEM values are shown on top of the 
corresponding bars.
Figure 4. Comparison between direct lysis and column-based RNA extraction on a cell dilution series. 
Direct lysis and column-based extraction were compared across a range of cell numbers (10, 100, and 1,000 
MDA-MB-468 cells), with two replicates at each cell number, for each method, and assessed by RT-qPCR. 
Direct lysis gave at least 1 Ct earlier than the column-based method. Error bars represent SD. Mean and SD 
values are shown on top of the corresponding bars.
www.nature.com/scientificreports/
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PicoPure extraction protocol alone takes a minimum of one hour, direct lysis method followed by RT 
reaction set up takes about ten minutes. In addition, IGEPAL CA-630 and BSA are low cost reagents. 
Thus the IGEPAL CA-630/BSA lysis method is faster, cheaper and more efficient than the column-based 
preparation.
The direct lysis method using the buffer containing both IGEPAL CA-630 and BSA is suitable for 
small number of cells, specifically one thousand cells or less. The line graph on Fig. 4 showed that the 
performance of the lysis method started to worsen at 1,000 cells, though it still gave better results than 
the Arcturus PicoPure column method. It has been shown that direct lysis with IGEPAL CA-630 works 
well up to a maximum of approximately one thousand cells11,25. Possible explanations for the decrease in 
the effectiveness of direct lysis on higher cell numbers include the higher concentration of RNases having 
a more marked impact, and other cell components reducing the RT efficiency. Thus, our method is not 
recommended for CTC samples enriched by a red blood cell (RBC) lysis method and density gradient 
centrifugation, due to a large amount of peripheral blood mononuclear cell (PBMC) contamination. On 
the other hand, CTC isolation by immunobeads and most current technologies using microfluidic CTC 
isolation, such as CTC-iChip26 or ClearCell Fx27, enable the isolation of single CTCs or pooled CTCs 
with the systemic removal of PBMCs and RBCs. Therefore, our direct lysis method is compatible and 
recommended for gene expression of CTCs isolated by such technologies.
In conclusion, we have found that a lysis solution composed of both of the mild non-ionic detergent 
IGEPAL CA-630 and BSA gives superior RNA recovery from low numbers of cells compared to previ-
ously reported solutions containing one or other of the components. In addition, direct lysis is a rapid, 
effective and economical alternative to a commercial column based extraction method when working 
with small cell numbers. This simple, reliable, time- and cost-effective method is suitable for gene expres-
sion studies of samples with low cell number, such as CTC studies, in which recovery can range from a 
single cell to several hundreds of cells.
Methods
Cell culture. The breast cancer cell lines used in this study (MDA-MB-231, MCF7, BT549, and 
MDA-MB-468) were from the American Type Culture Collection (ATCC, Rockville, MD, USA). 
MDA-MB-468 and MCF7 cells were cultured in Dulbecco’s Modified Eagle Medium with high glu-
cose content (DMEM—Sigma-Aldrich, St. Louis, Missouri, USA) and supplemented with 10% Foetal 
Calf Serum (FCS—Sigma-Aldrich). MDA-MB-231 and BT549 were grown in Roswell Park Memorial 
Institute (RPMI)-1640 Medium (R8758, Sigma-Aldrich) supplemented with 10% FCS. All cells were 
grown in a humidified incubator (37 °C, 5% CO2).
Cell number preparation. Cell samples containing approximately 10, 100 or 1,000 cells were pre-
pared by serial dilution. The samples used to test conditions in parallel were prepared from one stock.
RNA preparation. RNA from small number of cells was isolated by one of the two methodologies: 
(1) a column-based method with the Arcturus PicoPure RNA Isolation kit (Applied Biosystems — Foster 
City, California, USA) or (2) direct lysis methods as described below.
RNA extraction using the Arcturus PicoPure RNA Isolation kit was performed according to the man-
ufacturer’s protocol. Briefly, 50 ul of extraction buffer was added to the cell pellet, followed by 30 min 
incubation at 42 °C. While the lysate was incubated, the column was wetted by adding 250 ul of condition 
buffer, followed by centrifugation at 16,000 × g for 1 min. 50 ul of 70% ethanol was then added to the 
lysate, mixed well and the whole mixture was transferred to the prepared columns. Columns were cen-
trifuged for 2 min at 100 × g, followed by centrifuging at 16,000 × g for 30 sec to remove flow through. 
100 ul of wash buffer 1 was added to the columns, which were then centrifuged for 1 min at 8,000 × g. 
After that, 100 ul of wash buffer 2 was added to the columns, which were then centrifuged for 1 min 
at 8,000 × g. Another 100 ul of wash buffer 2 was added to the columns. Columns were centrifuged at 
16,000 × g for 2 min. Another spin at 16,000 × g for 1 min was performed to remove the wash residue in 
the columns. Purification columns were transferred to new Eppendorf tubes and 11 ul of elution buffer 
was carefully added onto the column membrane. Columns were centrifuged at 1,000 × g for 1 min, and 
subsequently at 16,000 × g for 1 min to elute RNA. 10 ul of RNA solution was obtained.
Direct lysis methods used lysis solutions of either 0.3% IGEPAL CA-630 (Sigma-Aldrich) alone, 0.3% 
IGEPAL CA-630 in RT mix A, 0.1% bovine serum albumin (BSA, Sigma-Aldrich), the combination of 
0.3% IGEPAL CA-630 and 0.1% BSA, or water. 5 ul of each lysis solution (IGEPAL CA-630 alone, BSA 
alone, IGEPAL CA-630/BSA, and water) was added directly onto cell pellets, and the mixtures were 
incubated on ice for a maximum of 5 min. Another 5 ul of reverse transcription (RT) mix A (see below) 
were subsequently added to cell lysates to make a total of 10 ul. The mixture of cell lysate and RT mix 
were stored on ice until cDNA synthesis step. 10 ul of lysis solution with IGEPAL CA-630 in the RT mix 
A was added into the cell pellet, the mixture was on ice until cDNA synthesis step.
cDNA synthesis (gene specific priming). Gene-specific priming was used for all RT reactions. A 
standard reaction volume of 10 ul was used for the Arcturus PicoPure RNA Isolation kit and 20 ul if using 
direct lysis method for RNA preparation.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:12859 | DOi: 10.1038/srep12859
Briefly, for the 10 ul gene specific priming RT reaction volume (Arcturus kit), ‘RT Mix A’ comprised of 
0.5 ul primer pool [8 uM] (primers from Geneworks—Adelaide, South Australia, Australia, or Integrated 
DNA Technologies — Coralville, Iowa, USA; 0.4 ul of dNTP [25 mM] (Bioline Reagents—London, UK), 
0.5 ul SUPERase• In™ RNase inhibitor (Ambion—a Life Technologies subsidiary) and 0.6 ul of nuclease 
free water was prepared first. Half of the RNA extracted by the Arcturus kit (5 ul) was added to 2 ul 
volume of ‘Mix A’. 7 ul solution of Mix A and RNA was placed in a PCR block at 65 °C for 5 min. During 
this time, 3 ul of ‘RT Mix B’ including 2 ul of 5x Thermoscript cDNA synthesis buffer (Life Technologies), 
0.5 ul of 0.1M DTT (Life Technologies) and 0.5 ul of Thermoscript RT enzyme (Life Technologies) was 
made. When the PCR block was cooled down to 55 °C, ‘RT Mix B’ was placed in the block separately for 
2–3 min to achieve the hot-start. 3 ul of ‘RT Mix B’ was added to bring each reaction volume to 10 ul. The 
run was resumed and the 55 °C step was run for 1 hr, followed by 85 °C for 5 min and ending with 4 °C 
until collection. cDNA was stored long term at − 20 °C or at 4 °C if it was used immediately.
In the 20 ul gene specific priming RT reaction volume (for direct lysis), volumes of reagents were 
adjusted such that the concentration of each component was same as the 10 ul gene specific priming RT 
reaction volume for Arcturus column-based method. The procedure for the RT reactions is as described 
above.
RT-qPCR. All the quantitative PCR work was conducted on the Stratagene MX3000P (Stratagene, 
La Jolla, California, USA). Reactions were performed in 96-well plates; each well contained 20 ul quan-
titative PCR reaction. In brief, quantitative PCR setup initially involved the mixing of 2 x Premix and 
nuclease-free water, next the desired volume of each template was aliquoted into its respective tube and 
the premix/water mixture added to each template. Each 20 mL of 2 x Premix consisted of: 3.2 mL DMSO, 
4 mL 10X PCR Gold Buffer, 12.08 mL nuclease-free H2O, 100 ul 1M Mg(CH3COO)2, 80 ul 100 mM 
dATP, 80 ul 100 mM dTTP , 80 ul 100 mM dCTP , 80 ul 100 mM dGTP, 1 ul SYBR® Green 1 and 200 ul 
AmpliTaq® Gold. For each gene, tubes were prepared and labeled for all the templates and non-template 
control and the appropriate volume of each primer pool was aliquoted into the labeled tubes. The pre-
mix/water/template was added into each respective tube. Once the premix/water/template/primer mix-
ture was made, three aliquots of 20 ul were made from a given tube into each well of the 96-well plate 
as three technical replicates for PCR. In each 20 ul PCR reaction, there were 10 ul of 2 x premix, 1 ul 
of 5 uM primer pool, 0.5 ul cDNA template and 8.5 ul water. Thermal cycling conditions were 95 °C for 
10 min, 95 °C for 30 sec followed by 60 °C for 1 min repeated for 40 cycles, and finally the dissociation 
step of 95 °C for 1 min followed by 60 °C for 30 sec and then 95 °C for 30 sec.
Statistical Analysis. All statistical analyses were performed using GraphPad Prism 6. Data from the 
comparison of five lysis solutions across different cells lines was analysed by repeated measure one-way 
ANOVA, with each lysis solution compared to IGEPAL CA-630/BSA by the Holm-Sidak’s multiple com-
parison tests. Reported p values are multiplicity adjusted. Data from the comparison of the IGEPAL 
CA-630/BSA solution and the Arcturus PicoPure column across different cell numbers was analysed by 
paired t-test.
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